197 related articles for article (PubMed ID: 23892220)
21. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
22. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
[TBL] [Abstract][Full Text] [Related]
23. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
24. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
25. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
26. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
27. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
[TBL] [Abstract][Full Text] [Related]
28. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
Tunn UW; Canepa G; Kochanowsky A; Kienle E
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
[TBL] [Abstract][Full Text] [Related]
29. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.
Wilcox C; Kautto A; Steigler A; Denham JW
Oncology; 2012; 82(1):56-8. PubMed ID: 22310055
[TBL] [Abstract][Full Text] [Related]
31. Pathologic effects of testosterone deprivation.
Sprenkle PC; Fisch H
Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
[TBL] [Abstract][Full Text] [Related]
32. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects.
Schubert M; Jockenhövel F
J Endocrinol Invest; 2005; 28(3 Suppl):23-7. PubMed ID: 16042356
[TBL] [Abstract][Full Text] [Related]
33. [Management of the side effects of androgenic deprivation].
Lebret T; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S338-42. PubMed ID: 19070813
[TBL] [Abstract][Full Text] [Related]
34. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
35. [Prostate cancer and androgen deprivation: benefits of psychological counseling].
Frambati L; Weber K; Canuto A; Miralbell R; Zilli T; Pichard C; Joly C; Voison N; Santos JF
Rev Med Suisse; 2013 Feb; 9(373):369-70, 372-3. PubMed ID: 23477070
[TBL] [Abstract][Full Text] [Related]
36. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
37. [Metabolic disorder after androgen deprivation therapy in patients with prostate cancer].
Yuan JQ; Zhang XW; Xu T; Wang XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):468-72. PubMed ID: 21906460
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation therapy for prostate cancer.
Bahnson R
J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
[No Abstract] [Full Text] [Related]
39. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
Galvão DA; Taaffe DR; Spry N; Newton RU
Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
[TBL] [Abstract][Full Text] [Related]
40. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
